Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026164 | 0.86 | LMNA (0.36) | GRIA1ALDH1A1LMNATP53SMN1; SMN2 | |
| SCHEMBL2027341 | 0.86 | MEN1 (0.36) | GRIA1LMNATP53SMN1; SMN2 | |
| SCHEMBL2016014 | 0.83 | KDM4A (0.32) | GRIA1 | |
| SCHEMBL2021495 | 0.81 | ZAP70 (0.40) | GRIA1ALDH1A1LMNATP53SMN1; SMN2 | |
| SCHEMBL2018866 | 0.79 | SMN1; SMN2 (0.42) | AURKAALDH1A1SMN1; SMN2 | |
| SCHEMBL2019511 | 0.79 | CSNK1E (0.35) | GRIA1 | |
| SCHEMBL2020328 | 0.79 | MAPT (0.42) | GRIA1TP53 | |
| SCHEMBL12638464 | 0.78 | AURKA (0.38) | AURKASMN1; SMN2GRM4HDAC8 | |
| SCHEMBL2026353 | 0.78 | TUBB4A (0.36) | ALDH1A1 | |
| SCHEMBL2019721 | 0.76 | ADORA3 (0.37) | GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | MKI67, TP53, THPO | AURKA 701/4885GRIA1 2924/4885ALDH1A1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.